This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Stock Bubble Debate in 14 Charts

Stock quotes in this article: CELG, CLDX, BLUE, ONTX, AEGR, RCPT, IMMU, ADHD, GILD, BIIB, AMGN, AMBI

BOSTON ( TheStreet) -- Checking in on the "Biotech Bubble: Yeah or Nay?" debate:

Before we start, let's agree the biotech sector is still having an unbelievable year. IBB Chart IBB data by YCharts

But biotech stocks have underperformed the broader market in the past month. IBB Chart IBB data by YCharts

Momentum-driven biotech stocks -- mostly small- and mid-cap -- have been hit with some serious selling over the past month. These were some of the sector's highest flyers, but not lately. I'm talking about stocks like:

Celldex Therapeutics (CLDX) : CLDX Chart CLDX data by YCharts

Clovis Oncology (CLVS): ^NBI Chart ^NBI data by YCharts

and Immunomedics (IMMU): IMMU Chart IMMU data by YCharts

2013 is shaping up to be a record year for biotech IPOs, but not all of the stellar debuts have staying power.

Bluebird Bio (BLUE): BLUE Chart BLUE data by YCharts

Alcobra Pharma (ADHD): ADHD Chart ADHD data by YCharts

Onconova Therapeutics (ONTX): ONTX Chart ONTX data by YCharts

Stemline Therapeutics (STML): STML Chart STML data by YCharts

Some biotech IPOs keep moving higher, like...

Receptos (RCPT) RCPT Chart RCPT data by YCharts

and Ambit BioSciences (AMBI): AMBI Chart AMBI data by YCharts

Big-cap biotech stocks are still performing strongly. Is there an investor flight to quality companies like Gilead Sciences (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG)? GILD Chart GILD data by YCharts

It's definitely NOT been a hard-knock life for orphan drug stocks in 2013: AEGR Chart AEGR data by YCharts

But investors have sent orphans begging in the past month: AEGR Chart AEGR data by YCharts

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs